IGEA Pharma N.V.
Miami University confirms high quality of IGEA’s COVID-19 rapid test
IGEA Pharma N.V. / Key word(s): Miscellaneous Miami University confirms high quality of IGEA’s COVID-19 rapid test Hoofddorp, the Netherlands, 6 May 2020. IGEA Pharma N.V. (SIX: IGPH) today announced that an evaluation by the Histocompatibility Laboratories, Department of Surgery, University of Miami – Miller School of Medicine suggests that the IGEA’s COVID-19 antibody rapid test appears to be superior to an established ELISA procedure in detecting IgM and IgG antibodies. Furthermore, an overall higher sensitivity of the IGEA’s rapid test over the ELISA procedure used has been observed using a RT PCR test comparison for the same specimens, and the PCR results comparison could suggest suitability in using the antibody-based test even in early stages of the infection. Vincenzo Moccia, CEO of IGEA: “This is a key step in proving reliability of the IGEA’s COVID-19 antibody-based test to the market. We hope now to consolidate such evidence with a positive and soon response to our submission EUA 200192 filed with the FDA on 6 April 2020 and start selling”. According to previous disclosures, IGEA has ensured the exclusivity of the antibody-based test under certain volume-based conditions for the US States New York, California, and Louisiana. *** About IGEA IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl Contacts Disclaimer The information contained in this press release has been carefully prepared. However, IGEA bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. IGEA does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons. This publication may contain specific forward-looking statements and assessments or intentions concerning IGEA and its business. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of IGEA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes no responsibility to update forward-looking statements or to adapt them to future events or developments, except as may be required by law. Additional features: Document: https://eqs-cockpit.com/c/fncls.ssp?u=QGMHGLOVSC Document title: 20200506 igea nv_press release End of ad hoc announcement |
Language: | English |
Company: | IGEA Pharma N.V. |
Siriusdreef 17 | |
2123 WT Hoofddorp | |
Netherlands | |
Phone: | +31 23 568 9494 |
E-mail: | info@igearesearch.com |
Internet: | www.igeapharma.nl |
ISIN: | NL0012768675 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1036839 |
End of Announcement | EQS Group News Service |